Emin Avşar

H. Groen, L. Sequist, E. Smit, 2017, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

First-In-Human Phase I Study of a Next-Generation, Oral, TGFβ Receptor 1 Inhibitor, LY3200882, in Patients with Advanced Cancer

W. Mason, D. Melisi, S. Estrem, 2021, Clinical Cancer Research.

First-In-Human Phase I Study of a Next-Generation, Oral, TGF b Receptor 1 Inhibitor, LY3200882, in Patients with Advanced Cancer

W. Mason, D. Melisi, S. Estrem, 2021 .

Abstract CT089: Phase Ib/II of CD40 agonistic antibody APX005M in combination with nivolumab (nivo) in subjects with metastatic melanoma (M) or non-small cell lung cancer (NSCLC)

G. Linette, Melissa L. Johnson, M. Edelman, 2019, Clinical Trials.

Adenosine acting via A1 receptors, controls the transition to status epilepticus-like behaviour in an in vitro model of epilepsy

R. Empson, Emin Avşar, E. Avşar, 2004, Neuropharmacology.

Phase I study of the selective BRAFV600inhibitor encorafenib (LGX818) combined with cetuximab and with or without the {alpha}-specific PI3K inhibitor BYL719 in patients with advanced BRAF-mutant colorectal cancer.

R. Bernards, J. Schellens, J. Tabernero, 2014 .

Phase II study of the HSP90 inhibitor AUY922 in patients with previously treated, advanced non-small cell lung cancer (NSCLC).

H. Groen, L. Sequist, E. Smit, 2012 .

Comparison of International Prognostic Index and NCCN-IPI in 324 patients with de novo diffuse large B-cell lymphoma: a multi-center retrospective analysis

M. Çetiner, A. Salihoglu, B. Ferhanoğlu, 2016, Leukemia & lymphoma.

A phase Ib/II study of galunisertib in combination with nivolumab in solid tumors and non-small cell lung cancer

S. Estrem, Jiangang Liu, L. Gandhi, 2023, BMC Cancer.

Ph1/2 study of Rova-T in combination with nivolumab (Nivo) ± ipilimumab (Ipi) for patients (pts) with 2L+ extensive-stage (ED) SCLC.

G. Curigliano, D. Morgensztern, B. Besse, 2019, Journal of Clinical Oncology.